≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

DOID Endpoint Browser

C3_SPINAL_CORD_CRANIAL_AND_OTHER_CNS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C72
  • Cause of death: ICD-9 — 192
  • Cause of death: ICD-8 — 192
  • Cause of death: excluded ICD-9 — 1921|1923|1928
  • Cancer registry: Topography ICD-O-3 — C72
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

71

4. Check minimum number of events

None

71

5. Include endpoints

None

71

6. Filter based on genotype QC (FinnGen only)

67

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 67 30 37
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 50.15 49.93 50.32

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
71
Matched controls
710
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
9391/3-C72.0
ICD-O-3
Ependymoma, NOS, of spinal cord
+∞
37.9
33
*
ABB10
NOMESCO Finland
Resection of lesion of spinal canal
+∞
34.1
30
*
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
+∞
28.0
25
*
C72.00
ICD-10 Finland
Malignant tumor of the spinal cord without histology
+∞
20.8
19
*
C72.01
ICD-10 Finland
Malignant tumor of the spinal cord grade II glioma
+∞
19.7
18
*
130
Kela drug reimbursment
Malignant tumour
+∞
17.4
16
*
H02AB02
ATC
dexamethasone; systemic
63.7
17.0
19
*
C72.09
ICD-10 Finland
Malignant tumor of the spinal cord other histology
+∞
16.3
15
*
D43.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Spinal cord
+∞
15.1
14
*
N03AX16
ATC
[U] pregabalin
6.5
13.8
35
93
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
57.2
12.4
14
*
M03BX01
ATC
baclofen; systemic
57.2
12.4
14
*
D33.43
ICD-10 Finland
Spinal cord
+∞
11.8
11
*
L28
ICPC
Limited function/disability (L)
5.9
10.7
25
60
D33.4
ICD-10 Finland
Benign neoplasm: Spinal cord
+∞
10.7
10
*
D33.40
ICD-10 Finland
Benign glioma of the spinal cord (grade I)
+∞
10.7
10
*
ZXE20
NOMESCO Finland
More than three and less than five hours
6.4
10.3
21
44
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
13.0
10.3
18
18
A03FA01
ATC
metoclopramide; systemic, rectal
6.4
10.0
20
41
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
64.1
10.0
11
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
26.0
9.8
13
6
WX408
NOMESCO Finland
General anesthesy, balanced
4.9
9.6
31
97
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
9.6
9
*
D33.41
ICD-10 Finland
Myxopapillary epndymoma of the spinal cord (grade I)
+∞
9.6
9
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
14.2
9.1
15
13
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
5.3
9.0
23
59
WF002
NOMESCO Finland
Radical radiotherapy
101.6
8.6
9
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
17.3
8.6
13
9
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
25.6
8.3
11
5
R4110
NOMESCO Finland
Physiotherapy
4.2
8.0
32
116
A04AA01
ATC
ondansetron; systemic, rectal
28.6
7.8
10
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
7.7
17
38
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
18.2
7.5
11
7
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
7.4
7
*
C72.0
ICD-10 Finland
Malignant neoplasm: Spinal cord
+∞
7.4
7
*
Z51.5
ICD-10 Finland
Palliative care
33.8
7.3
9
*
R50.9
ICD-10 Finland
Fever, unspecified
4.8
7.1
19
50
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.0
6.8
15
23
JN4BD
NOMESCO Finland
Extensive body CT
9.7
6.7
13
16
L03AA13
ATC
pegfilgrastim; parenteral
76.4
6.5
7
*
N03AE01
ATC
clonazepam; systemic
9.1
6.5
13
17
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
8.0
6.4
14
21
N02AA05
ATC
oxycodone; systemic
6.2
6.4
17
34
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
R33
ICD-10 Finland
Retention of urine
7.6
6.2
14
22
XKC03
NOMESCO Finland
Water cystometry
16.9
6.1
9
6
XX3DW
NOMESCO Finland
Time consuming IT work
10.6
6.0
11
12

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
11
32.04
18.43
1.3
1.2
—
—
—
0
0
23
44
7.25
12.52
4.9
10.2
1.81
1.47
mmol/l
0.20
18
37
39
155
4.36
8.73
2.7
1.9
—
—
—
0
0
44
222
3.58
6.41
7.3
5.8
1.20
1.22
mmol/l
1.39
44
203
17
35
6.05
6.26
6.2
9.1
24.98
24.87
mmol/l
0.04
17
35
27
107
3.46
5.64
6.0
3.5
—
—
—
0
0
44
248
3.04
4.89
7.9
5.7
1.19
1.22
mmol/l
1.60
39
211
16
52
3.68
4.41
6.1
8.7
104.25
104.44
mmol/l
0.06
16
52
14
44
3.72
4.03
3.4
10.6
—
—
—
0
0
8
11
8.03
3.97
3.4
1.2
—
—
—
0
0
33
175
2.65
3.89
3.1
1.6
—
—
—
0
0
6
6
10.76
3.56
1.5
1.2
—
—
—
0
0
11
28
4.45
3.46
5.4
13.4
1.35
1.42
%
0.08
11
28
11
28
4.45
3.46
5.4
13.4
95.38
94.35
%
0.70
11
28
11
28
4.45
3.46
5.4
13.4
0.73
0.72
%
0.01
11
28
6
7
9.21
3.33
6.3
1.0
—
—
—
0
0
8
15
5.86
3.29
3.9
5.7
—
—
—
0
0
38
229
2.42
3.29
18.0
12.6
1.29
1.34
inr
—
10
62
6
9
7.15
2.93
4.3
8.0
3.83
3.73
mmol/l
—
6
9
26
140
2.35
2.81
5.4
2.4
—
—
—
0
0
8
19
4.60
2.77
3.9
5.6
—
—
—
0
0
39
251
2.23
2.75
11.6
5.2
—
—
—
0
0
26
144
2.27
2.61
3.2
2.6
—
—
—
0
0
6
12
5.35
2.45
4.3
6.9
1.02
1.64
mmol/l
—
6
12
43
309
1.99
2.06
18.8
5.8
3.56
3.97
e9/l
0.67
37
264
37
258
1.91
1.89
7.9
3.2
9.46
15.13
umol/l
2.62
37
242
5
12
4.39
1.85
3.2
1.3
781.00
450.67
mg/l
—
5
12
35
243
1.87
1.78
16.5
7.1
0.00
0.00
e9/l
-0.00
27
184
22
131
1.98
1.76
13.8
4.1
—
—
—
0
0
14
70
2.25
1.73
1.3
1.7
—
—
—
0
0
6
19
3.35
1.70
9.8
2.9
1.45
1.08
%
—
6
19
10
44
2.48
1.64
1.3
1.7
—
—
—
0
0
38
277
1.80
1.61
11.1
4.8
0.04
0.04
e9/l
0.38
32
231
8
33
2.60
1.59
7.4
1.1
—
—
—
0
0
38
278
1.79
1.58
11.1
4.7
0.53
0.55
e9/l
0.27
33
233
39
288
1.79
1.57
11.7
4.7
0.13
0.19
e9/l
2.69
32
247
13
67
2.15
1.50
1.8
1.9
—
—
—
0
0
28
190
1.78
1.48
3.7
3.1
144.80
41.87
e6/l
0.53
23
120
38
284
1.73
1.43
11.2
4.9
1.63
2.02
e9/l
2.15
33
245
0
38
0.00
1.39
0.0
2.3
—
—
—
0
0
15
87
1.92
1.27
4.1
2.2
2.46
2.43
mmol/l
0.57
15
69
5
19
2.75
1.23
11.4
2.9
0.62
0.61
%
—
5
19
22
147
1.72
1.20
4.3
3.2
7.41
7.39
ph
—
6
21
44
353
1.65
1.19
8.1
3.4
—
22.67
—
0
6
15
231
0.56
1.18
2.9
2.7
—
—
—
0
0
5
20
2.61
1.17
4.2
1.5
—
—
—
0
0
8
40
2.12
1.16
11.1
3.5
—
—
—
0
0
8
40
2.12
1.16
1.5
1.1
—
—
—
0
0
23
160
1.65
1.07
1.3
1.5
—
—
—
0
0
46
379
1.61
1.06
3.1
3.4
—
—
—
0
0
45
370
1.59
1.04
5.8
3.5
—
—
—
0
0
49
412
1.61
1.02
9.6
4.7
78.20
74.21
u/l
0.49
49
374
26
191
1.57
0.96
4.1
3.2
18.33
51.98
ng/l
1.24
15
122
11
65
1.82
0.88
2.1
1.7
—
—
—
0
0
8
48
1.75
0.82
1.3
1.4
—
—
—
0
0
6
33
1.89
0.81
11.0
3.8
1.23
1.21
mmol/l
—
6
28
0
26
0.00
0.80
0.0
1.5
—
207.60
—
0
15
0
26
0.00
0.80
0.0
2.8
—
—
—
0
0
64
594
1.78
0.76
22.8
11.8
139.55
139.79
mmol/l
0.36
64
574
7
40
1.83
0.74
2.1
2.7
—
—
—
0
0
18
130
1.52
0.70
7.3
3.2
0.00
0.00
estimate
—
9
42
7
43
1.70
0.69
5.0
2.5
—
—
—
0
0
8
51
1.64
0.63
2.1
1.6
2.04
1.50
%
—
8
43
63
586
1.67
0.61
21.4
9.7
26.12
20.92
mg/l
0.52
58
432
6
35
1.78
0.59
1.5
1.6
0.19
0.22
g/l
—
6
30
0
23
0.00
0.59
0.0
1.2
—
—
—
0
0
13
95
1.45
0.48
1.4
1.7
—
—
—
0
0
10
69
1.52
0.47
2.0
1.2
—
—
—
0
0
24
199
1.31
0.43
2.0
1.8
87.91
96.61
pmol/l
0.44
11
96
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
5
36
1.42
0.39
4.8
2.3
—
—
—
0
0
11
144
0.72
0.38
1.1
1.3
—
1.23
—
0
39
64
612
1.46
0.33
23.6
11.4
66.80
76.69
umol/l
3.87
64
612
17
140
1.28
0.31
3.0
3.4
—
—
—
0
0
64
655
0.77
0.31
32.6
14.7
6.65
6.58
e9/l
0.10
64
639
64
655
0.77
0.31
32.3
14.6
30.10
30.18
pg
0.14
64
644
64
655
0.77
0.31
32.5
14.7
4.44
4.56
e12/l
1.00
64
638
64
655
0.77
0.31
32.7
14.8
132.45
136.99
g/l
1.48
64
644
64
654
0.78
0.30
32.4
14.7
242.41
247.59
e9/l
0.20
64
638
64
654
0.78
0.30
32.4
14.7
90.45
90.39
fl
0.04
64
643
8
66
1.24
0.28
1.3
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
3.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
3.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
30
274
1.16
0.20
5.6
3.1
0.00
0.00
estimate
—
9
42
7
58
1.23
0.19
1.7
1.6
—
—
—
0
0
29
267
1.15
0.17
5.7
3.1
0.00
0.00
estimate
—
9
46
14
121
1.20
0.16
1.4
1.9
—
—
—
0
0
5
61
0.81
0.08
1.2
1.1
—
—
—
0
0
28
270
1.06
0.04
6.4
4.5
0.00
0.00
estimate
—
9
44
15
141
1.08
0.04
2.1
3.3
22.90
53.31
mg/l
—
9
95
13
133
0.97
0.00
4.1
2.6
—
—
—
0
0
61
606
1.05
0.00
15.8
9.0
—
—
—
0
0
15
149
1.01
0.00
2.3
3.9
2.63
7.01
mg/mmol
—
9
99
14
144
0.97
0.00
7.6
3.2
—
—
—
0
0
6
69
0.86
-0.00
1.3
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
0.31
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
62
0.96
-0.00
1.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.52
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
1.13
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
7.24
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
204.56
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
298.33
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
2.26
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_SPINAL_CORD_CRANIAL_AND_OTHER_CNS – Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).